Microcap Ledger Longeveron Inc. $LGVN
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Miami, FL
- Fiscal year end
- December 31
What the company doesAI summary of filing
Longeveron Inc. is a clinical-stage biotechnology company developing laromestrocel, an allogeneic bone marrow-derived mesenchymal stem cell therapy, for multiple indications including Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease, pediatric dilated cardiomyopathy, and aging-related frailty. The company manufactures laromestrocel at its cGMP-compliant facility in Miami, Florida for use in clinical trials and a patient registry in The Bahamas, and is pursuing regulatory approval with an ongoing Phase 2b trial in HLHS and planned Phase 2 trials in other indications. Longeveron is pre-revenue from product sales, though it generates limited revenue from contract manufacturing services for third parties and patient registry fees in The Bahamas. [10-K 2026-03-17]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $685.0K | −$10.81M | −$10.02M | $10.08M | [10-Q 2026-08-12] |
| FY ended Dec 2025 | $1.20M | −$22.70M | −$18.64M | $4.66M | [10-K 2026-03-17] |
| FY ended Dec 2024 | $2.39M | −$15.97M | −$13.87M | $19.23M | [10-K 2026-03-17] |
- Quarterly cash burn
- −$5.01M
- Cash runway Estimate
- ~6 months
Capital structure and dilution
- Shelf registration
- S-1 filed 2026-04-10; declared effective 2026-04-17 [S-1 2026-04-10]
Listing status
Current status: 3 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-03-25. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-03-25 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-03-25] |
| 2026-03-09 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-03-09] |
| 2025-09-26 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-09-26] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-10-01 | Jhaveri Nirav S. | other | 742 | $2.59 | [4 2026-10-05] |
| 2026-10-01 | Willard Stephen H | other | 1,987 | $2.59 | [4 2026-10-05] |
| 2026-10-01 | Agafonova Nataliya | other | 2,913 | $2.59 | [4 2026-10-05] |
| 2026-10-01 | Lehr Paul T | other | 2,253 | $2.59 | [4 2026-10-05] |
| 2026-10-01 | Blass Devin | other | 2,520 | $2.59 | [4 2026-10-05] |
| 2026-08-19 | Lehr Paul T | grant | 286,000 | — | [4 2026-08-21] |
| 2026-08-19 | Hajjar Roger Joseph | grant | 36,000 | — | [4 2026-08-21] |
| 2026-08-17 | Jhaveri Nirav S. | grant | 300,000 | — | [4 2026-08-25] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-23 | 8-K | Other events |
| 2026-09-14 | 8-K | Other events |
| 2026-09-10 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-24 | 8-K | Charter, bylaws or fiscal year change; Regulation FD disclosure |
| 2026-08-19 | 8-K | Director or officer change |
| 2026-08-13 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-12 | 8-K | Results of operations |
| 2026-08-12 | 10-Q | Quarterly report |
| 2026-08-10 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-07-29 | 8-K | Other events |
| 2026-07-14 | 8-K | Director or officer change |
| 2026-07-08 | 8-K | Director or officer change |
Alerts for $LGVN
Email me when Longeveron Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.